Fatty acids and insulin resistance: a perfect storm - PubMed (original) (raw)
Fatty acids and insulin resistance: a perfect storm
Seung-Hoi Koo et al. Mol Cell. 2006.
Free article
Abstract
VLDL levels are elevated in type II diabetes, where they contribute to the risk of coronary heart disease. A study by Wolfrum and Stoffel (2006) shows that the forkhead protein Foxa2 stimulates hepatic VLDL production in concert with the coactivator PGC-1beta and that insulin inhibits this process by inactivating Foxa2.
Similar articles
- Foxa2, a novel transcriptional regulator of insulin sensitivity.
Puigserver P, Rodgers JT. Puigserver P, et al. Nat Med. 2006 Jan;12(1):38-9. doi: 10.1038/nm0106-38. Nat Med. 2006. PMID: 16397559 No abstract available. - Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion.
Wolfrum C, Stoffel M. Wolfrum C, et al. Cell Metab. 2006 Feb;3(2):99-110. doi: 10.1016/j.cmet.2006.01.001. Cell Metab. 2006. PMID: 16459311 - Elevated hepatocyte levels of the Forkhead box A2 (HNF-3beta) transcription factor cause postnatal steatosis and mitochondrial damage.
Hughes DE, Stolz DB, Yu S, Tan Y, Reddy JK, Watkins SC, Diehl AM, Costa RH. Hughes DE, et al. Hepatology. 2003 Jun;37(6):1414-24. doi: 10.1053/jhep.2003.50253. Hepatology. 2003. PMID: 12774021 - Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
Adiels M, Olofsson SO, Taskinen MR, Borén J. Adiels M, et al. Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1225-36. doi: 10.1161/ATVBAHA.107.160192. Arterioscler Thromb Vasc Biol. 2008. PMID: 18565848 Review. - Fatty acid-induced atherogenic changes in extracellular matrix proteoglycans.
Rodriguéz-Lee M, Bondjers G, Camejo G. Rodriguéz-Lee M, et al. Curr Opin Lipidol. 2007 Oct;18(5):546-53. doi: 10.1097/MOL.0b013e3282ef534f. Curr Opin Lipidol. 2007. PMID: 17885426 Review.
Cited by
- Nitrotyrosine, Nitrated Lipoproteins, and Cardiovascular Dysfunction in Patients with Type 2 Diabetes: What Do We Know and What Remains to Be Explained?
Jakubiak GK, Cieślar G, Stanek A. Jakubiak GK, et al. Antioxidants (Basel). 2022 Apr 27;11(5):856. doi: 10.3390/antiox11050856. Antioxidants (Basel). 2022. PMID: 35624720 Free PMC article. Review. - Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance.
Choi SH, Ginsberg HN. Choi SH, et al. Trends Endocrinol Metab. 2011 Sep;22(9):353-63. doi: 10.1016/j.tem.2011.04.007. Epub 2011 May 26. Trends Endocrinol Metab. 2011. PMID: 21616678 Free PMC article. Review. - Lysosomal acid lipase regulates VLDL synthesis and insulin sensitivity in mice.
Radović B, Vujić N, Leopold C, Schlager S, Goeritzer M, Patankar JV, Korbelius M, Kolb D, Reindl J, Wegscheider M, Tomin T, Birner-Gruenberger R, Schittmayer M, Groschner L, Magnes C, Diwoky C, Frank S, Steyrer E, Du H, Graier WF, Madl T, Kratky D. Radović B, et al. Diabetologia. 2016 Aug;59(8):1743-52. doi: 10.1007/s00125-016-3968-6. Epub 2016 May 6. Diabetologia. 2016. PMID: 27153842 Free PMC article. - Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis.
Koo SH. Koo SH. Clin Mol Hepatol. 2013 Sep;19(3):210-5. doi: 10.3350/cmh.2013.19.3.210. Epub 2013 Sep 30. Clin Mol Hepatol. 2013. PMID: 24133660 Free PMC article. Review. - FoxO1 integrates insulin signaling to VLDL production.
Kamagate A, Dong HH. Kamagate A, et al. Cell Cycle. 2008 Oct;7(20):3162-70. doi: 10.4161/cc.7.20.6882. Epub 2008 Oct 27. Cell Cycle. 2008. PMID: 18927507 Free PMC article. Review.